|
Final diagnosis correct
|
|
Exposure + obstruction b
|
758 (17.6)
|
0–60.0
|
< 0.001
|
9.8–23.3
|
< 0.001
|
|
Exposure + obstruction b + symptoms
|
369 (8.6)
|
0–41.3
|
< 0.001
|
0.7–14.0
|
< 0.001
|
|
Evaluation of the clinical presentation
|
|
Dyspnea registered
|
820 (19.0)
|
0–94.9
|
< 0.001
|
2.7–31.8
|
< 0.001
|
|
Dyspnea registered by mMRC
|
479 (11.1)
|
0–77.8
|
< 0.001
|
2.5–21.4
|
< 0.001
|
|
Cough and sputum registered
|
1099 (25.5)
|
0–94.4
|
< 0.001
|
0.9–49.6
|
< 0.001
|
|
Sputum color registered (n = 789 with chronic bronchitis)
|
358 (45.4)
|
0–77.9
|
< 0.001
|
19.2–77.0
|
< 0.001
|
|
Asthma symptoms registered
|
856 (19.9)
|
0–86.7
|
< 0.001
|
0.2–35.3
|
< 0.001
|
|
Exacerbations in the previous year registered
|
3507 (81.4)
|
2.6–100
|
< 0.001
|
62.0–95.6
|
< 0.001
|
|
Evaluation of therapies
|
|
Current smoking status registered
|
1874 (43.5)
|
0–100
|
< 0.001
|
18.2–66.1
|
< 0.001
|
|
Exercise registered
|
1950 (45.3)
|
0–100
|
< 0.001
|
13.9–74.5
|
< 0.001
|
|
Influenza vaccination registered
|
3777 (87.7)
|
43.9–100
|
< 0.001
|
79.1–96.6
|
< 0.001
|
|
Pneumococcal vaccination registered
|
2991 (69.4)
|
2.5–100
|
< 0.001
|
31.5–95.0
|
< 0.001
|
|
Adverse effects registered
|
173 (4.0)
|
0–100
|
< 0.001
|
1.6–6.9
|
< 0.001
|
|
Treatment adherence registered
|
610 (14.2)
|
0–94.9
|
< 0.001
|
5.3–27.4
|
< 0.001
|
|
Inhaler satisfaction registered
|
195 (4.5)
|
0–47.6
|
< 0.001
|
0.8–6.9
|
< 0.001
|
|
Evaluation of complementary tests used
|
|
Spirometry solicited
|
520 (12.1)
|
0–80.0
|
< 0.001
|
4.7–23.7
|
< 0.001
|
|
COPD assessment test administered
|
46 (1.1)
|
0–18.8
|
< 0.001
|
0–2.6
|
< 0.011
|
|
Sputum culture solicited
|
43 (1.0)
|
0–21.7
|
< 0.001
|
0–3.9
|
< 0.001
|
|
Alpha1-antitrypsin solicited (n = 4199 with no previous determination)
|
5 (0.1)
|
0–7.7
|
< 0.001
|
0–0.2
|
0.896
|
|
Alpha1-antitrypsin solicited at any time in the clinical record
|
114 (2.6)
|
0–23.8
|
< 0.001
|
0.4–7.4
|
< 0.001
|
